RUO vs IUO vs IVD Labeling: When Research-Use and Investigational-Use Products Become Regulated Diagnostics

Why RUO and IUO Labeling Matters More Than Ever

The boundary between research-use and clinical diagnostic products has become one of the most actively enforced regulatory fronts in the IVD industry. In 2024 and 2025, FDA issued warning letters to at least two manufacturers — Agena Bioscience (March 2024) and DRG Instruments GmbH (March 2025) — for marketing RUO-labeled products that FDA determined were intended for clinical diagnostic use. With FDA's LDT rule vacated by the U.S. District Court in March 2025, many observers expect FDA to increase scrutiny of RUO-labeled components as an alternative lever for oversight of laboratory-developed tests.

Under FDA regulations, merely placing an RUO or IUO label on an IVD product does not automatically exempt it from premarket requirements. FDA evaluates the "totality of the circumstances" — including labeling, marketing, distribution patterns, and customer base — to determine a product's true intended use.

This guide provides a practical, decision-tree-driven approach for IVD manufacturers, reagent suppliers, and distributors to understand where the regulatory lines are drawn and how to stay on the right side of them.

Definitions: RUO, IUO, and IVD

Research Use Only (RUO)

An RUO product is an IVD product in the laboratory research phase of development. Per 21 CFR 809.10(c)(2)(i), all labeling must bear the statement: "For Research Use Only. Not for use in diagnostic procedures."

Key characteristics:

• The product is in the laboratory research phase of development and is not represented as an effective IVD product
• It has no intended medical purpose or objective
• It is exempt from most FDA regulatory controls (with specific labeling requirements as the exception)
• It does not require 510(k) clearance, PMA approval, or IDE application

FDA recognizes two types of RUO products:

1. Development-stage IVDs where the product itself is the subject of the research
2. Non-clinical research tools — instruments, systems, and reagents intended for nonclinical laboratory research with goals other than developing a commercial IVD product

Investigational Use Only (IUO)

An IUO product is being shipped or delivered for product testing prior to full commercial marketing. Per 21 CFR 809.10(c)(2)(ii), labeling must state: "For Investigational Use Only. The performance characteristics of this product have not been established."

Key characteristics:

• Typically used in comparison studies with archived or fresh clinical specimens
• May contribute to a clinical diagnosis, but confirmation by another medically accepted test is always required
• IUO devices are distinct from IDE devices, which undergo testing for safety and effectiveness and are subject to full IDE regulations (21 CFR Part 812)
• Exempt from IDE regulations only when the testing is noninvasive, does not require invasive sampling with significant risk, does not introduce energy into a subject, and is not used as a standalone diagnostic

In Vitro Diagnostic (IVD)

An IVD product is a reagent, instrument, or system intended for use in the diagnosis of disease or other conditions, including determination of state of health, to cure, mitigate, treat, or prevent disease. IVD products require premarket clearance (510(k)) or approval (PMA), manufacturing controls under 21 CFR Part 820 / QMSR, and registration and listing.

Regulatory Framework

FDA Regulations and Guidance

EU IVDR Perspective

Under the EU In Vitro Diagnostic Regulation (EU 2017/746), Article 2(45) specifies that a device intended for research purposes without any medical objective shall not be deemed a device for performance study. The IVDR distinguishes RUO products from regulated IVDs and performance study devices based on the absence of a medical intended purpose. RUO products are not defined in the IVDR and carry no regulatory requirements — but the moment a medical intended purpose is assigned, the product falls within IVDR scope.

When RUO Products Cross the Line

FDA applies a "totality of the circumstances" test. The following table identifies practices that are inconsistent with RUO designations:

Red Flags: Distribution Practices Inconsistent with RUO

The Agena Bioscience Warning Letter (2024)

In March 2024, FDA issued a warning letter to Agena Bioscience for promoting its RUO-labeled MassARRAY system for clinical diagnostic use. FDA cited:

• Product descriptions relating to clinical or diagnostic uses
• Claims about supporting identification, diagnosis, or monitoring of specific diseases
• Comparisons to diagnostic tests and cleared medical devices
• Language suggesting the product could be used as part of an LDT

This was the first RUO-related warning letter in over five years.

The DRG Instruments Warning Letter (2025)

In March 2025, FDA issued a warning letter to DRG Instruments GmbH for its RUO-labeled salivary cortisol assay. FDA determined the product was intended for clinical use based on:

• Distribution records showing sales to clinical laboratories with no research activity
• Website claims including "Simple and patient-friendly measurement of hormone profiles" and "Can be performed also by patients"
• Changes to assay components and clinical claims without a new 510(k) submission

FDA classified the product as both misbranded and adulterated. This was only the fifth RUO-related enforcement action since FDA finalized its 2013 guidance.

Decision Tree: Is Your Product RUO, IUO, or IVD?

Use this decision tree to determine your product's regulatory status:

START: Does the product have a medical intended purpose?
│
├─ YES → It is an IVD. Requires 510(k)/PMA, QMSR, registration.
│
├─ NO → Is it being used in investigations to establish performance?
│   │
│   ├─ YES → Is it exempt from IDE under 21 CFR 812?
│   │   │
│   │   ├─ YES → It qualifies as IUO.
│   │   │   Label: "For Investigational Use Only.
│   │   │   The performance characteristics of this product
│   │   │   have not been established."
│   │   │
│   │   └─ NO → It requires an IDE. Follow 21 CFR Part 812.
│   │       Label: "CAUTION—Investigational device.
│   │       Limited by Federal (or United States) law to
│   │       investigational use."
│   │
│   └─ NO → Is it used solely for nonclinical laboratory research?
│       │
│       ├─ YES → It qualifies as RUO.
│       │   Label: "For Research Use Only.
│       │   Not for use in diagnostic procedures."
│       │
│       └─ NO → Re-evaluate. If used for any clinical purpose,
│           it is likely an IVD regardless of label.

RUO vs IUO vs IVD Comparison Table

Marketing Language: What to Avoid

One of the most common triggers for FDA enforcement is marketing language that implies clinical diagnostic use. The following table provides examples:

Distributor and Customer Behavior Risk

Even if a manufacturer's labeling is compliant, distributor and customer behavior can trigger FDA scrutiny. Key risk areas:

Distributor Risk Factors

Customer Certification Programs

Some manufacturers implement certification programs requiring customers to attest that they will use RUO products only for research purposes. While FDA's 2013 final guidance removed the draft's explicit certification requirements, certification remains a risk-mitigation best practice.

Enforcement Risk Assessment

Historical Enforcement Actions

Enforcement Trend Analysis

FDA issued 32 enforcement letters targeting medical device marketing violations in 2025. While RUO-specific actions remain relatively rare (only five since 2013), the trend is accelerating:

• 2013–2023: Three RUO-related actions
• 2024: One action (Agena)
• 2025: One action (DRG), with more expected

The 2025 Covington annual summary noted that FDA issued 19 device QSR warning letters through September 2025, surpassing the 12 issued in the same period of 2024 — a 58% increase year-over-year. This broader enforcement posture suggests RUO scrutiny will continue to intensify.

EU IVDR RUO Considerations

Under the IVDR, the regulatory status of RUO products is determined by intended purpose:

If a laboratory or other entity assigns a medical purpose to an RUO product, that entity may itself become the manufacturer under IVDR Article 5(5) in-house device rules and assume full regulatory obligations.

Practical Compliance Checklist

For RUO Product Manufacturers

• All labeling bears the required statement: "For Research Use Only. Not for use in diagnostic procedures."
• No clinical diagnostic claims in marketing materials, website, or product literature
• No comparisons to FDA-cleared or approved diagnostic products
• Distribution records reviewed to identify clinical laboratory customers
• Sales and marketing staff trained annually on RUO communication boundaries
• Distributor agreements include RUO compliance clauses
• No clinical application training provided to customers
• Customer-facing materials reviewed by regulatory affairs
• Website and digital marketing audited for implied clinical claims
• Customer certification program implemented (recommended)

For IUO Product Manufacturers

• All labeling bears: "For Investigational Use Only. The performance characteristics of this product have not been established."
• IDE exemption criteria confirmed (noninvasive, no significant risk sampling, no energy introduction)
• Comparison study protocols documented
• Confirmation by another medically established diagnostic product or procedure required
• Distribution limited to qualified investigators
• Study agreements specify investigational use only

The LDT Connection: Why RUO Enforcement May Increase

The vacatur of FDA's LDT rule in March 2025 has created regulatory uncertainty. Key implications:

1. LDTs commonly use RUO components: Many laboratory-developed tests incorporate RUO-labeled reagents. FDA may use RUO enforcement as a lever to regulate LDT inputs even without the LDT rule.

2. Component-level authority: FDA has long asserted jurisdiction over IVD components, including reagents intended for use as finished medical devices, whether labeled for standalone use or not.

3. CDER and CBER pathways remain: Even without the LDT rule, CDER and CBER may request validation data for companion diagnostics and single-site tests, relying on CDRH consultation.

4. Congressional attention: Ongoing legislative proposals for LDT regulation may be accompanied by increased enforcement of RUO boundaries.

Key Takeaways

1. Labels alone don't create exemptions. FDA looks at the totality of circumstances — labeling, marketing, distribution, and customer base — to determine intended use.

2. Marketing language is the top enforcement trigger. Claims about clinical accuracy, disease detection, or diagnostic performance on an RUO product will draw FDA scrutiny.

3. Enforcement is accelerating. After years of relative inactivity, FDA issued RUO warning letters in consecutive years (2024, 2025), and observers expect this trend to continue.

4. Distributor behavior matters. Even compliant manufacturers face risk if distributors market RUO products to clinical laboratories or provide clinical application support.

5. EU rules are conceptually similar but structurally different. The IVDR ties regulatory status to the presence or absence of a medical intended purpose, with no formal RUO category.

6. The LDT vacatur may increase RUO scrutiny. With the LDT rule struck down, FDA may focus more on RUO-labeled components as an alternative pathway to oversight of clinical laboratory testing.

Sources

• FDA. "Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only — Guidance for Industry and FDA Staff." November 2013.
• 21 CFR 809.10 — In Vitro Diagnostic Products for Human Use: Labeling.
• 21 CFR 812 — Investigational Device Exemptions.
• FDA Warning Letter to Agena Bioscience, MARCS-CMS 665159 (March 2024).
• FDA Warning Letter to DRG Instruments GmbH, MARCS-CMS 700918 (March 2025).
• Mintz. "FDA Warning Letter Is a Stark Reminder That If You Claim Your Product Is RUO, It Has to Be RUO." April 2024.
• JDSupra / Sheppard Mullin. "What to Watch: Potential Increase in Enforcement of RUO Diagnostics." 2025.
• King & Spalding. "2025 Year in Review: FDA Drug and Device Advertising and Promotion Enforcement."
• Qualomics. "RUOs, LDTs, and FDA Enforcement: Just Because They Lost Doesn't Mean They're Gone." July 2025.
• Johner Institute. "Laboratory Products 'For Research Use Only' (RUO)."
• EU IVDR, Regulation (EU) 2017/746, Articles 2(45) and 5(5).
• FDA. "CLIA Waiver by Application." Updated 2025.